Sangamo Therapeutics, Inc (SGMOQ) stock
SGMOQOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.10−0.01 (-8.17%)
Close on Oct 19, 2026Market cap $39.43MP/E –Yield –
Sangamo Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Sangamo Therapeutics's revenue for the twelve months ending Mar 31, 2026 was $34.56M, down 45.8% year over year. For fiscal 2025 it was $39.55M, down 31.6% from the year before. Over ten years it grew 0.0% a year on average. The highest annual figure on record is $176.23M in fiscal 2023.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $39.55M | -31.6% |
| FY2024 | Dec 31, 2024 | $57.80M | -67.2% |
| FY2023 | Dec 31, 2023 | $176.23M | +58.3% |
| FY2022 | Dec 31, 2022 | $111.30M | +0.5% |
| FY2021 | Dec 31, 2021 | $110.70M | -6.3% |
| FY2020 | Dec 31, 2020 | $118.19M | +15.4% |
| FY2019 | Dec 31, 2019 | $102.43M | +21.3% |
| FY2018 | Dec 31, 2018 | $84.45M | +131.0% |
| FY2017 | Dec 31, 2017 | $36.57M | +88.6% |
| FY2016 | Dec 31, 2016 | $19.39M | -51.0% |
| FY2015 | Dec 31, 2015 | $39.54M | -13.8% |
| FY2014 | Dec 31, 2014 | $45.87M | +90.1% |
| FY2013 | Dec 31, 2013 | $24.13M | +11.4% |
| FY2012 | Dec 31, 2012 | $21.66M | +109.9% |
| FY2011 | Dec 31, 2011 | $10.32M | -50.4% |
| FY2010 | Dec 31, 2010 | $20.81M | -6.2% |
| FY2009 | Dec 31, 2009 | $22.19M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026 | Mar 31, 2026 | $1.44M | -77.6% |
| Q4 FY2025 | Dec 31, 2025 | $14.23M | +88.4% |
| Q3 FY2025 | Sep 30, 2025 | $581.00K | -98.8% |
| Q2 FY2025 | Jun 30, 2025 | $18.31M | +5042.1% |
| Q1 FY2025 | Mar 31, 2025 | $6.44M | +1238.3% |
| Q4 FY2024 | Dec 31, 2024 | $7.55M | +269.8% |
| Q3 FY2024 | Sep 30, 2024 | $49.41M | +425.8% |
| Q2 FY2024 | Jun 30, 2024 | $356.00K | -94.8% |
| Q1 FY2024 | Mar 31, 2024 | $481.00K | -99.7% |
| Q4 FY2023 | Dec 31, 2023 | $2.04M | -92.5% |
| Q3 FY2023 | Sep 30, 2023 | $9.40M | -64.5% |
| Q2 FY2023 | Jun 30, 2023 | $6.84M | -76.7% |
| Q1 FY2023 | Mar 31, 2023 | $157.96M | +459.5% |
| Q4 FY2022 | Dec 31, 2022 | $27.23M | -2.7% |
| Q3 FY2022 | Sep 30, 2022 | $26.46M | -7.4% |
| Q2 FY2022 | Jun 30, 2022 | $29.38M | +5.4% |
| Q1 FY2022 | Mar 31, 2022 | $28.23M | +7.4% |
| Q4 FY2021 | Dec 31, 2021 | $27.99M | +8.5% |
| Q3 FY2021 | Sep 30, 2021 | $28.56M | -50.6% |
| Q2 FY2021 | Jun 30, 2021 | $27.87M | +29.3% |
| Q1 FY2021 | Mar 31, 2021 | $26.28M | +101.0% |
| Q4 FY2020 | Dec 31, 2020 | $25.80M | -53.0% |
| Q3 FY2020 | Sep 30, 2020 | $57.76M | +163.1% |
| Q2 FY2020 | Jun 30, 2020 | $21.55M | +22.8% |
| Q1 FY2020 | Mar 31, 2020 | $13.08M | +62.0% |
| Q4 FY2019 | Dec 31, 2019 | $54.85M | +104.4% |
| Q3 FY2019 | Sep 30, 2019 | $21.96M | -6.8% |
| Q2 FY2019 | Jun 30, 2019 | $17.55M | -18.1% |
| Q1 FY2019 | Mar 31, 2019 | $8.07M | -36.1% |
| Q4 FY2018 | Dec 31, 2018 | $26.84M | +105.2% |
| Q3 FY2018 | Sep 30, 2018 | $23.56M | +99.5% |
| Q2 FY2018 | Jun 30, 2018 | $21.42M | +159.5% |
| Q1 FY2018 | Mar 31, 2018 | $12.64M | +269.0% |
| Q4 FY2017 | Dec 31, 2017 | $13.08M | +46.6% |
| Q3 FY2017 | Sep 30, 2017 | $11.81M | +318.4% |
| Q2 FY2017 | Jun 30, 2017 | $8.25M | +122.9% |
| Q1 FY2017 | Mar 31, 2017 | $3.43M | – |
| Q4 FY2016 | Dec 31, 2016 | $8.92M | – |
| Q3 FY2016 | Sep 30, 2016 | $2.82M | – |
| Q2 FY2016 | Jun 30, 2016 | $3.70M | – |
See a number that looks wrong?